ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

A New LC-MS/MS Assay for the Quantification of A¦Â40 and A¦Â42 in Plasma: Validation and Clinical Performance

REDDI Lab Symposium 2023

Clemson, SC, Aug 18, 2023

Poster presentation:?

Authors:?Weber DM, Kim JC, Goldman SM, Racke MK, Clarke NJ

Specialty:?Neurology

Related content

Audio Podcast
Alzheimer¡¯s disease: A new generation of screenings and therapies on the horizon
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
Publication
The small HDL particle hypothesis of Alzheimer's disease
Conference Presentation
A new LC-MS/MS Assay for the Quantification of A¦Â40 and A¦Â42 in Plasma: Validation and Clinical Performance
Conference Presentation
The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.